Abstract: The present invention provides a method of preparing and purifying echinocandin-type compounds, such as pneumocandin Bo, WF 11899A, and echinocandin B. These compounds are fermentation products that are used to prepare semi-synthetic products such as the antifungal products Caspofungin, Mycafungin, and Anidulafungin.

Abstract: The present invention provides Caspofungin and salts thereof substantially free of Caspofungin C0 and salts thereof. The present invention also provides processes for the preparation of said Caspofungin and salts thereof and processes for the determination of the amount of Caspofungin C0 and salts thereof present in Caspofungin and salts thereof. The present invention further provides pharmaceutical compositions comprising said Caspofungin and salts thereof.

Abstract: Provided is ascomycin that has a low level of an FK523 impurity, and pimecrolimus that has a low level of a 32-deoxy-32-epichloro-FK523 impurity, methods of preparing them, and the use of such pimecrolimus for preparing a pharmaceutical composition.

Abstract: Provided is a method for obtaining a macrolide, especially tacrolimus, ascomycin, pimecrolimus, sirolimus, or everolimus, from biomatter.

Abstract: The present invention provides a method of preparing and purifying echinocandin-type compounds, such as pneumocandin Bo, WF 11899A, and echinocandin B. These compounds are fermentation products that are used to prepare semi-synthetic products such as the antifungal products Caspofungin, Mycafungin, and Anidulafungin.

Abstract: The invention provides a process for the chromatographic purification of Tacrolimus, using a silver modified sorbent, selected from the group consisting of silver modified aluminum oxide, zirconium oxide, styrene divinylbenzene copolymer, adsorption resin, cation exchange resin, anion exchange resin, reverse phase silica gel, and cyano silica-gel, and separating the Tacrolimus chromatographically with the silver modified sorbent as a stationary phase.

Abstract: Provided is a method for crystallization and purification of a macrolide such as tacrolimus, sirolimus, pimecrolimus, or everolimus that includes the step of providing a combination of a macrolide, and a polar solvent, dopolar aprotic solvent, or hydrocarbon solvent at pH of 7 or above.

Abstract: Provided is a method of purifying a macrolide, especially tacrolimus, that includes loading macrolide onto a bed of sorption resin and eluting with a suitable eluent such as a combination of water and tetrahydrofuran.

Abstract: Provided is a method of purifying a macrolide, especially tacrolimus, that includes loading macrolide onto a bed of sorption resin and elting with a suitable eluent such as a combination of water and tetrahydrofuran.

Abstract: The invention provides a method for crystallization and purification of tacrolimus that includes the step of providing a combination of a macrolide and a polar solvent, dopolar aprotic solvent, or hydrocarbon solvent at pH of 7 or above. The invention also provides a novel crystalline form of tacrolimus.

Abstract: The present invention provides amorphous tacrolimus in a free drug particulate form. Also provided are methods for preparing amorphous tacrolimus, and a tablet containing amorphous tacrolimus.

Abstract: The invention provides pure tacrolimus and a method for purifying tacrolimus in which a loading charge of tacrolimus is placed in juxtaposition with a bed of wet sorption resin, the loading charge and bed are eluted with an eluent comprising THF, acetonitrile, or a combination thereof, water, and, optionally, at least one additional organic solvent, the heart cut of the eluent is collected, and tacrolimus is collected, the tacrolimus is further crystallized and recrystallized until obtaining a reduced level of impurities.

Abstract: The present invention provides a fermentation process for producing lipstatin comprising the steps of: a) preparing a fermentation medium containing a lipstatin-producing microorganism comprising an oil and an assimilable carbon source, wherein the wt/wt ratio of oil and assimilable carbon source is regulated to achieve an optimal lipstatin biosynthesis by the microorganism; and b) feeding the fermentation medium with an emulsifier, wherein the emulsifier provides an optimal viscosity for the fermentation medium and optimal pH during the fermentation to permit fermentation for lipstatin production. The disclosed process also provides a process for extracting a lipstatin from a fermentation broth.

Abstract: Provided is a method of purifying a macrolide, especially tacrolimus, that includes loading macrolide onto a bed of sorption resin and elting with a suitable eluent such as a combination of water and tetrahydrofuran.

Abstract: The present invention provides a fermentation process for producing lipstatin comprising the steps of: a) preparing a fermentation medium containing a lipstatin-producing microorganism comprising an oil and an assimilable carbon source, wherein the wt/wt ratio of oil and assimilable carbon source is regulated to achieve an optimal lipstatin biosynthesis by the microorganism; and b) feeding the fermentation medium with an emulsifier, wherein the emulsifier provides an optimal viscosity for the fermentation medium and optimal pH during the fermentation to permit fermentation for lipstatin production. The disclosed process also provides a process for extracting a lipstatin from a fermentation broth.

Abstract: Provided is a method for obtaining a macrolide, especially tacrolimus, ascomycin, pimecrolimus, sirolimus, or everolimus, from biomatter.

Abstract: Provided is a method for crystallization and purification of a macrolide such as tacrolimus, sirolimus, pimecrolimus, or everolimus that includes the step of providing a combination of a macrolide, and a polar solvent, dopolar aprotic solvent, or hydrocarbon solvent at pH of 7 or above.

Abstract: The present invention is directed to a process of converting lipstatin to orlistat by catalytic hydrogenation. The present invention further discloses novel crystalline solid orlistat forms, designated form I and form II and methods for their preparation.

Abstract: The present invention is directed to a process of converting lipstatin to orlistat by catalytic hydrogenation. The present invention further discloses novel crystalline solid orlistat forms, designated form I and form II and methods for their preparation.

Abstract: The present invention is directed to a process of converting lipstatin to orlistat by catalytic hydrogenation. The present invention further discloses novel crystalline solid orlistat forms, designated form I and form II and methods for their preparation.